Page 515 - Traité de chimie thérapeutique 6 Médicaments antitumoraux

17. MITOXANTRONE 473

Bis[(aminoalkyl)amino]-5,8-dihydroxyanthracene-9, 10-diones, J. Med. Chem., 1991,
34, 2373-2380.
RAUNER W. et al., Preparation of pure 1,4,5,8-tetrahydroxy-2,3-dihydro-9,10-anthrace-
nedione. Ger. Offen. DE 4,035,478, 1991. Chem. Abst., 1991, 115, 158757.
HATTORI M., Oyes, anthraquinone, in Encyclopedia of Chemical technology, Othmer K.,
ed., John Wiley and Sons, New York, 1993 (4° edition), vol. 8, 602-671.
McLAFFERTY F.W., TURECEK F., Interpretation of mass spectra, University Science
Books, Mill Valley, California, 1993 (48 edition), 220 et 245.
CHANG P., An improved procedure for the preparation of 4,5-dinitrochrysazin, Synth.
Commun., 1994, 24, 931-937.
CHANG P., CHENG C.C., An improved practical synthesis of leuco-1,4,5,8-tetrahy-
droxyanthraquinone, Synth. Commun., 1995, 25, 1893-1900.

PHARMACOCINÉTIQUE, MÉTABOLISME, MÉCANISMES D'ACTION,
RÉSISTANCES
TRAGANOS F. et al., Action of dihydroxyanthraquinone on cell cycle progression and
survival of a variety of cultured mammalian cells, CancerRes., 1980, 40, 671-681.
KAPUSCINSKI J. et al., Interactions of a new antitumor agent, 1,4-dihydroxy-5,8-bis 2-
(2-hydroxyethyl) aminoethylamino-9,10-anthracenedione, with nucleic acids, Bio-
chem. Pharmac0l., 1981, 30, 231-240.
KHARASCH E.D., NOVAK R.F., lnhibitory effects of anthracenedione antineoplastic
agents on hepatic and cardiac lipid peroxidation, J. Pharmacol. Exp. Ther., 1983, 226,
500-506.
FRANK P, NOVAK R.F., Mitoxantrone and bisantrene inhibition of platelet aggregation
and prostaglandin E, production in vitro, Biochem. Pharmacol., 1985, 34, 3609-3614.
LOWN J.W. et al., Characteristics of the binding of the anti-cancer agents mitoxantrone
and ametantrone and related structures to DNAs, Biochemistry, 1985, 24, 4028-4035.
FIDLER J.M. et al., Selective lmmunomodulation by the antineoplastic agent mitoxan-
trone. 1. Suppression of 8 lymphocyte function, J. lmmunol., 1986, 137, 727-732.
KRISHNAMOORTHY C.R. et al., Stopped-flow kinetic analysis of the interaction of
anthraquinone anticancer drugs with calf thymus DNA, poly[d(G-C)].poly(d(G-C], and
poly [d(A-T].poly[d(A-T], Biochemistry, 1986, 25, 5933-5940.
FISHER G.R., PATTERSON L.H., Oxidative activation of the antitumor agent mitoxan-
trone, J. Pharm. Pharmacol., 1989, 41, 150.
RESZKA K. et al., Interaction of the peroxldase-derived metabolite of mitoxantrone with
nucleic acids. Evidence for covalent binding of 'C-labeled drug, Biochem. Pharma-
col., 1989, 38, 4253-4260.
DENNY W.A., WAKELIN L.P.G., Kinetics of the binding of mitoxantrone, ametantrone
and analogs to DNA: relationship with binding mode and antitumor activity, Anti-
cancerDrug Des., 1990, 5, 189-200.
FOX M.E., SMITH P.J., Long-term inhibition of DNA synthesis and the persistance of
trapped topoisomerase Il complexes ln determining the toxicity of the antitumor DNA
intercalators mAMSA and mitoxantrone, Cancer Res., 1990, 50, 5813-5818.
BLANZ J. et al., Evidence for oxidative activation of mitoxantrone in human, pig, and rat,
Drug Metab. Dispos., 1991, 19, 871-880.